Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.
Arrhythmias
Cardio-oncology
Cardiotoxicity
Hypertension 5’ AMP-activated protein kinase (AMPK)
Intracellular signaling
Phosphoinositide 3-kinase (PI3K) signaling
Tyrosine kinase inhibitors (TKIs)
Vascular endothelial growth factor receptor (VEGFR)
Journal
Heart failure clinics
ISSN: 1551-7136
Titre abrégé: Heart Fail Clin
Pays: United States
ID NLM: 101231934
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
entrez:
19
6
2022
pubmed:
20
6
2022
medline:
22
6
2022
Statut:
ppublish
Résumé
Tyrosine kinase inhibitors (TKIs) are used to treat several cancers; however, a myriad of adverse cardiotoxic effects remain a primary concern. Although hypertension (HTN) is the most common adverse effect reported with TKI therapy, incidents of arrhythmias (eg, QT prolongation, atrial fibrillation) and heart failure are also prevalent. These complications warrant further research toward understanding the mechanisms of TKI-induced cardiotoxicity. Recent literature has given some insight into the intracellular signaling pathways that may mediate TKI-induced cardiac dysfunction. In this article, we discuss the cardiotoxic effects of TKIs on cardiomyocyte function, signaling, and possible treatments.
Identifiants
pubmed: 35718417
pii: S1551-7136(22)00004-6
doi: 10.1016/j.hfc.2022.02.003
pmc: PMC10391230
mid: NIHMS1916890
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
425-442Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL160590
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL134616
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, patents received or pending, or royalties.
Références
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Circ Res. 2021 Jun 25;129(1):e21-e34
pubmed: 33934611
Mol Cancer. 2018 Feb 19;17(1):58
pubmed: 29455648
Science. 1997 Oct 24;278(5338):687-9
pubmed: 9381178
Drug Des Devel Ther. 2016 Aug 01;10:2443-59
pubmed: 27536065
Basic Res Cardiol. 2018 Jun 15;113(4):29
pubmed: 29905892
Circulation. 2008 Jul 1;118(1):84-95
pubmed: 18591451
Arq Bras Cardiol. 2014 Nov;103(5):403-409
pubmed: 25229355
Chem Res Toxicol. 2020 Jan 21;33(1):125-136
pubmed: 31840498
J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):387-398
pubmed: 29706106
Haematologica. 2015 Mar;100(3):e77-9
pubmed: 25425690
Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2793-800
pubmed: 9409257
Circulation. 2019 May 28;139(22):2570-2584
pubmed: 30922063
Mol Cancer Ther. 2003 May;2(5):471-8
pubmed: 12748309
Cardiooncology. 2017;3:
pubmed: 29497565
Oncologist. 2007 Apr;12(4):426-37
pubmed: 17470685
Recent Prog Horm Res. 1986;42:143-205
pubmed: 3526451
J Clin Ultrasound. 2016 May;44(4):221-30
pubmed: 26875513
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
Blood. 2005 Apr 1;105(7):2640-53
pubmed: 15618470
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9349-54
pubmed: 9689083
J Physiol. 2020 Jul;598(14):2923-2939
pubmed: 30816576
PLoS One. 2013 Dec 11;8(12):e82979
pubmed: 24349409
Nat Med. 2006 Aug;12(8):908-16
pubmed: 16862153
Am J Hypertens. 2014 Jan;27(1):3-13
pubmed: 24168915
Crit Rev Oncol Hematol. 2015 May;94(2):228-37
pubmed: 25577572
Clin Cancer Res. 2009 Oct 1;15(19):6232-40
pubmed: 19789325
J Am Coll Cardiol. 2012 Dec 11;60(23):2384-90
pubmed: 23141499
J Clin Invest. 2007 Dec;117(12):4044-54
pubmed: 18060038
J Biol Chem. 1997 Jun 13;272(24):15442-51
pubmed: 9182576
CA Cancer J Clin. 2013 Jul-Aug;63(4):249-79
pubmed: 23716430
Clin Transl Sci. 2009 Feb;2(1):15-25
pubmed: 20376335
Sci Transl Med. 2012 Apr 25;4(131):131ra50
pubmed: 22539774
Cell. 1997 Oct 17;91(2):231-41
pubmed: 9346240
Drug Saf. 2013 Jun;36(6):413-26
pubmed: 23620170
J Natl Cancer Inst. 2011 May 4;103(9):763-73
pubmed: 21527770
Acta Derm Venereol. 2012 Mar;92(2):218-9
pubmed: 22307953
Front Cardiovasc Med. 2021 Feb 01;7:630480
pubmed: 33598481
Am J Pathol. 2009 Sep;175(3):998-1009
pubmed: 19679877
Cancer Chemother Pharmacol. 2012 Mar;69(3):773-80
pubmed: 22033636
J Am Coll Cardiol. 2006 Dec 5;48(11):2258-62
pubmed: 17161256
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
J Natl Cancer Inst. 2010 May 5;102(9):596-604
pubmed: 20351338
Mol Cancer Ther. 2007 Jul;6(7):2012-21
pubmed: 17620431
Ann Oncol. 2020 Feb;31(2):171-190
pubmed: 31959335
Eur Heart J. 2016 Sep 21;37(36):2768-2801
pubmed: 27567406
Nat Rev Cancer. 2007 May;7(5):332-44
pubmed: 17457301
Hypertension. 2017 Aug;70(2):220-226
pubmed: 28630211
Ann Oncol. 2005 Aug;16(8):1391-7
pubmed: 15905307
J Clin Oncol. 2010 Jan 20;28(3):475-80
pubmed: 20008644
Circulation. 2010 Dec 21;122(25):2669-79
pubmed: 21098440
PLoS One. 2017 Feb 3;12(2):e0171137
pubmed: 28158206
Circulation. 2001 Jul 17;104(3):330-5
pubmed: 11457753
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cell Death Dis. 2016 Jul 28;7(7):e2317
pubmed: 27468693
Blood Rev. 2018 Jul;32(4):289-299
pubmed: 29454474
J Clin Invest. 1999 Sep;104(6):709-19
pubmed: 10491406
Curr Treat Options Cardiovasc Med. 2014 Sep;16(9):335
pubmed: 25099086
Hypertension. 2012 Jan;59(1):151-7
pubmed: 22124432
Biochem J. 2002 Jun 15;364(Pt 3):593-611
pubmed: 11931644
Circ Res. 2011 Dec 9;109(12):1401-9
pubmed: 21998323
Am J Cardiol. 2015 Apr 15;115(8):1090-4
pubmed: 25711434
Circulation. 2006 Jul 4;114(1 Suppl):I290-5
pubmed: 16820588
Lancet Haematol. 2015 May;2(5):e186-93
pubmed: 26688093
Europace. 2007 Sep;9 Suppl 4:iv16-22
pubmed: 17766320
Oncotarget. 2015 Nov 3;6(34):35589-601
pubmed: 26431495
Front Physiol. 2021 Oct 14;12:744023
pubmed: 34721066
J Mol Cell Cardiol. 2011 Oct;51(4):468-73
pubmed: 21276796
PLoS One. 2014 Jan 27;9(1):e87457
pubmed: 24475291
Circulation. 2006 Aug 15;114(7):637-44
pubmed: 16894033
Onco Targets Ther. 2018 Sep 25;11:6227-6237
pubmed: 30288058
J Cancer Res Clin Oncol. 2021 Aug;147(8):2407-2420
pubmed: 33725154
Clin Sci (Lond). 2021 Jan 15;135(1):71-100
pubmed: 33404052
J Am Soc Hypertens. 2018 Jun;12(6):409-425
pubmed: 29703600
Circ Arrhythm Electrophysiol. 2017 Aug;10(8):
pubmed: 28798022
Can J Cardiol. 2016 Jul;32(7):852-62
pubmed: 26968393
Cancer. 2013 Jun 1;119 Suppl 11:2131-42
pubmed: 23695925
Intern Med. 2021 Sep 15;60(18):2973-2977
pubmed: 33814488
Tumour Biol. 2020 Jul;42(7):1010428320941760
pubmed: 32662332
FASEB J. 2010 May;24(5):1467-78
pubmed: 20019242
Clin Cancer Res. 2003 Jan;9(1):327-37
pubmed: 12538485
J Clin Invest. 2010 Feb;120(2):472-84
pubmed: 20071776
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2304-9
pubmed: 16467148
Hypertension. 2010 Oct;56(4):675-81
pubmed: 20733093
Front Pharmacol. 2021 Apr 29;12:664181
pubmed: 33995090
J Clin Invest. 2003 Mar;111(5):617-25
pubmed: 12618516
PLoS One. 2012;7(3):e33407
pubmed: 22428044
Basic Clin Pharmacol Toxicol. 2020 Feb;126(2):166-180
pubmed: 31483925
Clin Cancer Res. 2009 Jun 15;15(12):4220-7
pubmed: 19509175
Am J Pathol. 2007 Nov;171(5):1431-40
pubmed: 17872976
Ann Oncol. 2007 Jun;18(6):1117
pubmed: 17586751
Can J Cardiol. 2019 Feb;35(2):153-159
pubmed: 30760421
Oncologist. 2009 Apr;14(4):378-90
pubmed: 19349511
Curr Opin Pharmacol. 2015 Apr;21:7-13
pubmed: 25500206
J Clin Invest. 2006 Jul;116(7):1865-77
pubmed: 16823487
J Mol Cell Cardiol. 2021 Jun;155:66-77
pubmed: 33667419
Clin Cancer Res. 2011 Jan 1;17(1):142-53
pubmed: 21081656
N Engl J Med. 2006 Jun 15;354(24):2531-41
pubmed: 16775234
J Biol Chem. 1998 Nov 13;273(46):30336-43
pubmed: 9804796
Toxicol Lett. 2016 Jun 11;252:50-61
pubmed: 27084042
JACC CardioOncol. 2021 Nov 16;3(5):619-634
pubmed: 34988471
J Am Coll Cardiol. 2008 Nov 25;52(22):1769-81
pubmed: 19022156
Clin Cancer Res. 2011 Oct 1;17(19):6130-9
pubmed: 21953501
J Am Soc Echocardiogr. 2017 Nov;30(11):1111-1118
pubmed: 28927558
Circ Res. 2004 Apr 2;94(6):e61-70
pubmed: 15016728
J Am Soc Echocardiogr. 2010 Apr;23(4):351-69; quiz 453-5
pubmed: 20362924
Nat Nanotechnol. 2016 Apr;11(4):378-87
pubmed: 26780659
Int J Mol Sci. 2018 Oct 20;19(10):
pubmed: 30347815
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):164-72
pubmed: 20728704
Ann Oncol. 2007 Nov;18(11):1906-7
pubmed: 17993633
Cardiooncology. 2015 Dec 7;1(1):6
pubmed: 33530150
Cardiovasc Res. 2009 Oct 1;84(1):54-63
pubmed: 19542178